Application of drug composition product

Abstract

The invention relates to application of drug composition product in curing diseases of the respiratory system. The effect of the drug composition product on curing the respiratory system diseases caused by infection of escherichia coli and klebsiella pneumoniae is better than the effect of the drug composition product on curing urinary system diseases caused by infection of the escherichia coli and the klebsiella pneumoniae.

Description

technical field

[0001] The present invention relates to the use of a pharmaceutical composition, in particular, the present invention relates to the use of a composition in the preparation of medicines for treating bacterial infections. Background technique

[0002] Compound 1 (shown in the chemical formula below) is a semi-synthetic antibiotic developed by the British Glaxo Company. Compound 2 (shown in the chemical formula below) is a semi-synthetic β-lactamase inhibitor. Compound 2 combined with β-lactam antibiotics can increase the antibacterial activity of β-lactam antibiotics.

[0003]

[0004] Compound 1 Compound 2

[0005] In recent years, due to the irrational application of antibacterial drugs, the resistance of bacteria to antibacterial drugs is increasing. With the increase of bacterial resistance, the infection caused by drug-resistant bacteria is difficult to control, which leads to an increase in the mortality rate of infection. Many antibiotics have a ...

Examples

Embodiment 1

[0069] Taking the composition of compound 1 and compound 2 with a mass ratio of 2:1 as an example, the infection of Escherichia coli and Klebsiella pneumoniae producing β-lactamase resistant to compound 1 single drug was studied through clinical experiments The clinical treatment effect of moderate and severe respiratory diseases caused by

[0070] According to the method described in the aforementioned human pharmacodynamic clinical trial (1), the subjects who meet the requirements of the clinical trial were screened, and a total of 20 subjects who met the experimental requirements were screened. ; Among them, 10 subjects with acute bronchitis, 6 subjects with acute exacerbation of chronic bronchitis and 4 subjects with bacterial pneumonia; They were divided into groups and treated for 14 days, and the therapeutic effect was evaluated according to the evaluation method described in the human pharmacodynamic clinical trial (3), and the experimental results shown in Table 3 wer...

Embodiment 2

[0075] Taking the composition with a mass ratio of compound 1 and compound 2 of 2:1 as an example, its clinical therapeutic effect on patients with complex urinary tract infection (moderate and severe) resistant to compound 1 single drug was studied through clinical experiments.

[0076] According to the method described in the aforementioned human pharmacodynamics clinical trial (1), the subjects meeting the clinical trial requirements were screened, and a total of 6 subjects meeting the experimental requirements were screened out. Bacterial culture and species identification of fluid) found that the bacteria infected by the screened subjects with complicated urinary tract infection were both Escherichia coli and Klebsiella pneumoniae, and the number of cases was similar to that of patients with respiratory diseases. comparability. The patients were treated for 14 days according to the dosage regimen described in the human pharmacodynamic clinical trial (2), and the therapeut...

technical field

[0001] The present invention relates to the use of a pharmaceutical composition, in particular, the present invention relates to the use of a composition in the preparation of medicines for treating bacterial infections. Background technique

[0002] Compound 1 (shown in the chemical formula below) is a semi-synthetic antibiotic developed by the British Glaxo Company. Compound 2 (shown in the chemical formula below) is a semi-synthetic β-lactamase inhibitor. Compound 2 combined with β-lactam antibiotics can increase the antibacterial activity of β-lactam antibiotics.

[0003]

[0004] Compound 1 Compound 2

[0005] In recent years, due to the irrational application of antibacterial drugs, the resistance of bacteria to antibacterial drugs is increasing. With the increase of bacterial resistance, the infection caused by drug-resistant bacteria is difficult to control, which leads to an increase in the mortality rate of infection. Many antibiotics have a ...

Examples

Embodiment 1

[0069] Taking the composition of compound 1 and compound 2 with a mass ratio of 2:1 as an example, the infection of Escherichia coli and Klebsiella pneumoniae producing β-lactamase resistant to compound 1 single drug was studied through clinical experiments The clinical treatment effect of moderate and severe respiratory diseases caused by

[0070] According to the method described in the aforementioned human pharmacodynamic clinical trial (1), the subjects who meet the requirements of the clinical trial were screened, and a total of 20 subjects who met the experimental requirements were screened. ; Among them, 10 subjects with acute bronchitis, 6 subjects with acute exacerbation of chronic bronchitis and 4 subjects with bacterial pneumonia; They were divided into groups and treated for 14 days, and the therapeutic effect was evaluated according to the evaluation method described in the human pharmacodynamic clinical trial (3), and the experimental results shown in Table 3 wer...

Embodiment 2

[0075] Taking the composition with a mass ratio of compound 1 and compound 2 of 2:1 as an example, its clinical therapeutic effect on patients with complex urinary tract infection (moderate and severe) resistant to compound 1 single drug was studied through clinical experiments.

[0076] According to the method described in the aforementioned human pharmacodynamics clinical trial (1), the subjects meeting the clinical trial requirements were screened, and a total of 6 subjects meeting the experimental requirements were screened out. Bacterial culture and species identification of fluid) found that the bacteria infected by the screened subjects with complicated urinary tract infection were both Escherichia coli and Klebsiella pneumoniae, and the number of cases was similar to that of patients with respiratory diseases. comparability. The patients were treated for 14 days according to the dosage regimen described in the human pharmacodynamic clinical trial (2), and the therapeut...

Images